Evidence map›Paper›PMID 40973918›Full record

ArticleStem cells translational medicine2025

Rapid manufacturing of angiogenic cellular collagen patches for ischemic cardiomyopathy.

Eric Pfrender, Sungwoo Kim, John A Farag, Shin Yajima, Yujiro Kawai, Koji Kawago, Umayr Syed, Gentaro Ikeda, Tsuyoshi Ueyama, Hiroyuki Takashima and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Eric PfrenderDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Sungwoo KimDepartment of Orthopedic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
John A FaragDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Shin YajimaDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Yujiro KawaiDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Koji KawagoDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Umayr SyedDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Gentaro IkedaStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, United States.
Tsuyoshi UeyamaDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States.
Hiroyuki TakashimaDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States.
Alex DalalDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Yuanjia ZhuDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.ORCID 0000-0001-5642-9883
Kenzo IchimuraStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, United States.ORCID 0000-0002-5734-335X
Yu LiuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, United States.
Seyedsina MoeinzadehDepartment of Orthopedic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Jayme KoltsovDepartment of Orthopedic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, United States.
Y Joseph WooDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.ORCID 0000-0002-2506-492X
Phillip C YangStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, United States.
Yunzhi P YangDepartment of Orthopedic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.
Yasuhiro ShudoDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, United States.ORCID 0000-0002-4545-1273

Funding

Systems Modeling Guided Bone regenerationU01AR069395 · NIAMS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI YANG, YUNZHI, ZHOU, XIAOBO · 2016 to 2021
$3.4M
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the HipR01AR072613 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B, YANG, YUNZHI · 2018 to 2022
$2.2M
Preclinical microphysiological tumor models for nuclear medicineR01CA268514 · NCI · STANFORD UNIVERSITY · PI Guillem Pratx, JOHN B SUNWOO · 2023 to 2026
$2.1M
Vascularization in bone tissue engineering constructsR01AR074458 · NIAMS · STANFORD UNIVERSITY · PI YANG, YUNZHI · 2019 to 2023
$1.7M
American Heart AssociationCareer Development 23CDA1038803Department of Defense W81XWH-20-1-0343Department of Defense W81XWH-22-1-0189NCI NIH HHS R01 CA268514NIAMS NIH HHS R01 AR072613NIAMS NIH HHS R01 AR074458NIAMS NIH HHS R01AR074458NIAMS NIH HHS U01 AR069395NIH HHS R01AR072613NIH HHS U01AR069395Stanford Cardiovascular Institute
6 · The paper itself

Abstract

backgroundOne in ten Americans carry a lifetime risk of ischemic heart failure, the most severe form of ischemic heart disease. Carrying a nearly 50% five‑year mortality rate, no interventional therapy exists to treat the underlying cause, microvascular malperfusion. In efforts to combat microvascular malperfusion, our group has utilized synergistic application of endothelial progenitor cells (EPCs) and smooth muscle cells (SMCs) to induce angiogenesis in ischemic myocardium.

methodsCells are then embedded into a rapidly manufacturable compressed collagen (CC) patch to provide a biosimilar scaffold ready for transplantation. The performance of the cellular compressed collagen patch was then tested on a rodent acute myocardial infarction model of ischemic heart failure.

resultsBy post‑transplantation Day 28, the cellular CC patch improved left ventricular ejection fraction when compared to an acellular CC patch and control (cellular: 49.1 ± 1.8%; acellular: 38.0 ± 2.6%; control: 39.2 ± 2.1%; ANOVA P = .0006). Cellular CC patch transplantation also induced mature angiogenesis as shown by arteriolar density (cellular: 1084 ± 98 αSMA+vWF+/mm2; acellular: 338 ± 57 αSMA+vWF+/mm2; control: 449 ± 39 αSMA+vWF+/mm2; ANOVA P = .0003) and vascular maturation index (cellular: 0.67 ± 0.04; acellular: 0.48 ± 0.02; and control: 0.46 ± 0.04, P = .001).

conclusionsIn conclusion, transplantation of a rapidly manufacturable EPC‑SMC‑based compressed collagen patch effectively rescues myocardial function by enhancing neovascularization and attenuating post‑infarction myocardial injury.

Indexed as

CardiomyopathiesCollagenEndothelial Progenitor CellsMyocardial IschemiaNeovascularization, PhysiologicAnimalsDisease Models, AnimalHumansMaleMyocardial InfarctionMyocytes, Smooth MuscleRatsTissue ScaffoldsCollagenangiogenesisbiomaterialscollagen patchendothelial progenitor cellsischemic cardiomyopathymyocardial infarctiontissue engineering

Identifiers

PMID40973918
PMCPMC12449208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.